Curocell’s RIMQARTO: The Secret Behind Its Expanded Second-Line Treatment Indication
AI 요약 정보
- Curocell seeks second-line RIMQARTO use for adult DLBCL
- Phase 3 trial compares RIMQARTO with standard care
- Trial planned for first half of 2027, pending IND approval